Cargando…

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial

BACKGROUND: The optimal treatment for oligometastatic prostate cancer (OMPC) is still on its way. Accumulating evidence has proven the safety and feasibility of radical prostatectomy and local or metastasis-directed radiotherapy for oligometastatic patients. The aim of this trial is to demonstrate t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xianzhi, Xiao, Yu-Tian, Yang, Yue, Ye, Yusheng, Chang, Yifan, Jiang, Lingong, Eftekhar, Md, Ren, Shancheng, Zhang, Huojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393665/ https://www.ncbi.nlm.nih.gov/pubmed/35980734 http://dx.doi.org/10.1177/10732748221120462

Ejemplares similares

Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial
por: Xiao, Yu-Tian, et al.
Publicado: (2020)

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial
por: Zhu, Xiaofei, et al.
Publicado: (2022)

Biologically effective doses of 60–70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial
por: Ye, Yusheng, et al.
Publicado: (2022)

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study
por: Zhu, Xiaofei, et al.
Publicado: (2020)

Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China
por: Zhao, Xianzhi, et al.
Publicado: (2021)

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
por: Sun, Hai-Bo, et al.
Publicado: (2020)

Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles
por: Zhu, Xiaofei, et al.
Publicado: (2020)

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
por: Parikh, Neil R., et al.
Publicado: (2019)

Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer
por: Baron, D., et al.
Publicado: (2023)

Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy
por: Zhu, Xiaofei, et al.
Publicado: (2021)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)
por: Gebauer, Florian, et al.
Publicado: (2021)

Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial
por: Zhang, Meng-xia, et al.
Publicado: (2019)

Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome
por: Riva, Giulia, et al.
Publicado: (2017)

Role of surgery in oligometastatic prostate cancer
por: Jenjitranant, Pocharapong, et al.
Publicado: (2019)

Brachytherapy for oligometastatic prostate cancer to the penis
por: Martz, Nicolas, et al.
Publicado: (2021)

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
por: Hong, D S, et al.
Publicado: (2019)

Neoadjuvant stereotactic radiosurgery for intracerebral metastases of solid tumors (NepoMUC): a phase I dose escalation trial
por: Diehl, Christian D., et al.
Publicado: (2019)

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
por: Radwan, Noura, et al.
Publicado: (2017)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
por: Privé, Bastiaan M., et al.
Publicado: (2020)

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
por: Decaestecker, Karel, et al.
Publicado: (2014)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
por: Hasan, Hamza, et al.
Publicado: (2020)

CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer
por: Sheikhbahaei, Sara, et al.
Publicado: (2020)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Oligometastatic prostate cancer: Reality or figment of imagination?
por: Foster, Corey C., et al.
Publicado: (2018)

Imaging modalities in synchronous oligometastatic prostate cancer
por: Futterer, Jurgen J., et al.
Publicado: (2018)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Oligometastatic carcinoma prostate – An overview of the last decade
por: Shah, Milap J, et al.
Publicado: (2023)

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)
por: Yoshida, Soichiro, et al.
Publicado: (2023)

Factors associated with de novo metastatic disease in invasive breast cancer: comparison of artificial neural network and logistic regression models
por: Qiu, Chunyan, et al.
Publicado: (2019)

A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam
por: Kestelyn, Evelyne, et al.
Publicado: (2020)

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China
por: Xu, Chenyang, et al.
Publicado: (2022)

MON-282 Treatment of Hyperprolactinemia with Ropinirole: An Open-Label Dose Escalation Study
por: Tsang, Amanda, et al.
Publicado: (2020)

Oligometastatic Prostate Cancer to the Navicular Bone: Case Report
por: Reyes, Diane K., et al.
Publicado: (2015)

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer
por: Miura, Yuji, et al.
Publicado: (2019)

Radiotherapy of oligometastatic prostate cancer: a systematic review
por: Rogowski, Paul, et al.
Publicado: (2021)

Oligometastatic prostate cancer: is it worth targeting the tip of the iceberg?
por: Supiot, Stéphane, et al.
Publicado: (2019)

The current role of precision surgery in oligometastatic prostate cancer
por: von Deimling, M., et al.
Publicado: (2022)

OLIGOPELVIS – GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer
por: Supiot, Stephane, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4kpdegndruq4dhlv55ggqbtk5n